REDWOOD CITY, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced 11 oral and poster presentations will be featured at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, held from April 25 – 30, 2025.
The first clinical data in non-small cell lung cancer from the Phase 1 study of zoldonrasib, a RAS(ON) G12D-selective inhibitor, will be featured in a late breaking oral presentation.
Details of the abstracts are listed below:
Revolution Medicines Oral Presentations:
| Title: | Preliminary safety and antitumor activity of zoldonrasib (RMC-9805), an oral, RAS(ON) G12D-selective, tri-complex inhibitor in patients with KRAS G12D non-small cell lung cancer (NSCLC) from a Phase 1 study in advanced solid tumors |
| Presenter: | Kathryn Arbour, M.D., Memorial Sloan Kettering Cancer Center |
| Abstract Number: | CT019 |
| Session: | New Frontiers in Precision Oncology |
| Date/Time: | April 27; 5:00 p.m. – 5:15 p.m. CST |
| Title: | Discovery of RMC-5127, an oral, RAS(ON) G12V-selective, noncovalent, tri-complex inhibitor |
| Presenter: | Anne Edwards, Ph.D. |
| Abstract Number: | ND06 |
| Session: | New Drugs on the Horizon: Part 2 |
| Date/Time: | April 27; 3:25 p.m. – 3:40 p.m. CST |
Revolution Medicines Poster Presentations:
| Title: | Early reduction in circulating tumor DNA (ctDNA) is associated with clinical activity of daraxonrasib (RMC-6236) in RAS mutant non-small cell lung cancer (NSCLC) |
| Presenter: | Jia Luo, M.D., Dana-Farber Cancer Institute |
| Abstract Number: | LB218 |
| Session: | Late-Breaking Research: Clinical Research 1 |
| Date/Time: | April 28; 2:00 p.m. – 5:00 p.m. CST |
| Title: | Mechanisms of resistance to the RAS(ON) multi-selective inhibitor daraxonrasib (RMC-6236) in RAS mutant PDAC and potential resolution with RAS(ON) combination therapies |
| Presenter: | Mallika Singh, Ph.D. |
| Abstract Number: | LB281 |
| Session: | Late-Breaking Research: Experimental and Molecular Therapeutics 3 |
| Date/Time: | April 29; 9:00 a.m. – 12:00 p.m. CST |
| Title: | Combination of RAS(ON) mutant-selective and multi-selective inhibitors sensitizes immune-refractory, RAS-driven preclinical models to immunotherapy |
| Presenter: | Mariela Moreno Ayala, Ph.D. |
| Abstract Number: | 6046 |
| Session: | Adaptive Immunity in Tumors / Oncogenic Pathway-Mediated Regulation of Inflammation and Tumor Immunity |
| Date/Time: | April 29; 2:00 p.m. – 5:00 p.m. CST |
Collaborator Presentations
| Title: | Distinct regulation of Cyclin D mediates heterogenous response to RAS inhibition in colorectal cancer models |
| Presenter: | Philip Choi, M.D., Ph.D., Memorial Sloan Kettering Cancer Center |
| Abstract Number: | LB293 |
| Session: | Late-Breaking Research: Experimental and Molecular Therapeutics 3 |
| Date/Time: | April 29; 9:00 a.m. – 12:00 p.m. CST |
| Title: | Combining RAS(ON) G12C-selective and RAS(ON) multi-selective inhibitors overcomes sotorasib resistance driven by KRAS G12C amplification or NRAS G13R mutation |
| Presenter: | Hitendra Singh Solanki, Ph.D., Moffitt Cancer Center |
| Abstract Number: | 5512 |
| Session: | Drug Resistance in Molecular Targeted Therapies 3 |
| Date/Time: | April 29; 2:00 p.m. – 5:00 p.m. CST |
| Title: | A RAS(ON) multi-selective inhibitor combination therapy triggers long-term tumor control through senescence-associated tumor-immune equilibrium in preclinical models of PDAC |
| Presenter: | Caroline Broderick, Ph.D., Memorial Sloan Kettering Cancer Center |
| Abstract Number: | 5336 |
| Session: | CDK Inhibitors |
| Date/Time: | April 29; 2:00 p.m. – 5:00 p.m. CST |
| Title: | Preclinical evaluation of RMC-7977, a multi-selective RAS(ON) inhibitor, as a therapeutic strategy for KRAS-mutant cholangiocarcinoma |
| Presenter: | Jingjing Jiang, Ph.D. |
| Abstract Number: | 5691 |
| Session: | Oncogenes, Tumor Suppressor Genes, and Gene Products as Targets for Therapy 2 |
| Date/Time: | April 29; 2:00 p.m. – 5:00 p.m. CST |
| Title: | Mechanisms of resistance to RAS-GTP inhibition in pancreatic cancer |
| Presenter: | Joshua H. Choe, Dana-Farber Cancer Institute |
| Abstract Number: | 5507 |
| Session: | Drug Resistance in Molecular Targeted Therapies 3 |
| Date/Time: | April 29; 2:00 p.m. – 5:00 p.m. CST |
| Title: | T-cell dependency of tumor regressions and complete responses with RAS(ON) multi-selective inhibition in preclinical models of PDAC |
| Presenter: | Margo I. Orlen, Penn Medicine |
| Abstract Number: | 6405 |
| Session: | Checkpoints and Modulators of Tumor Microenvironment |
| Date/Time: | April 29; 3:25 p.m. – 3:40 p.m. CST |
About Revolution Medicines, Inc.
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; and zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor, are currently in clinical development. The company anticipates that RMC-5127, a RAS(ON) G12V-selective inhibitor, will be its next RAS(ON) inhibitor to enter clinical development. Additional development opportunities in the company’s pipeline focus on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C). For more information, please visit www.revmed.com and follow us on LinkedIn.
Revolution Medicines Media & Investor Contact:
This email address is being protected from spambots. You need JavaScript enabled to view it.
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$77.58 |
| Daily Volume: | 0 |
| Market Cap: | US$15.000B |
November 05, 2025 October 27, 2025 October 16, 2025 September 29, 2025 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
